Effect of terazosin on sweating in patients with major depressive disorder receiving sertraline: A randomized controlled trial

International Journal of Psychiatry in Clinical Practice

Volumn 17, Issue 1, 2013, Pages 44-47

  Ghaleiha, Ali ^a   Shahidi, Kadijeh Moghadasian ^b   Afzali, Saeed ^a   Matinnia, Nasrin ^c  

^a HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Major depression; Sertraline; Sweating; Terazosin

Indexed keywords

PLACEBO; SERTRALINE; TERAZOSIN;

ADULT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DSM-IV; EVENING DOSAGE; FEMALE; HUMAN; HYPERHIDROSIS; HYPERHIDROSIS DISEASE SEVERITY SCALE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SWEATING; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADULT; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PRAZOSIN; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SWEATING; TREATMENT OUTCOME;

EID: 84873619657     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2012.687449     Document Type: Article

References (22)

1. Koenig AM, Thase ME. First-line pharmacotherapies for depression-what is the best choice? Pol Arch Med Wewn 2009;119:478-86
2. Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA. National trends in the outpatient treatment of depression. J Am Med Assoc 2002;287:203-9
3. Demling J, Beyer S, Kornhuber J. To sweat or not to sweat? A hypothesis on the effects of venlafaxine and SSRIs. Med Hypotheses 2010;74:155-7
4. Ashton AK, Weinstein WL. Cyproheptadine for drug-induced sweating. Am J Psychiatry 2002;159:874-5
5. Babbott SF, Pearson VE. Sertraline-related night sweats. Ann Intern Med 1999;130:242-3
6. Kiev A, Feiger A. A double-blind comparison of fl uvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 1997;58:146-52
7. Keller MB, Hirschfeld RM, Demyttenaere K, Baldwin DS. Optimizing outcomes in depression: focus on antidepressant compliance. Int Clin Psychopharmacol 2002;17:265-71
8. Kim WO, Kil HK, Yoon KB, Yoo JH. Treatment of generalized hyperhidrosis with oxybutynin in post-menopausal patients. Acta Derm Venereol 2010;90:291-3
9. Sadock BJ. Biological therapies Kaplan & Sadock 's Synopsis of psychiatry. 10th ed. Boston, MA: Wolters Kluwer, Lippincott Williams & Wilkins; 2007. p. 1083-91
10. Garber A, Gregory RJ. Benztropine in the treatment of venlafaxine-induced sweating. J Clin Psychiatry 1997;58:176-7
11. Tupker RA, Harmsze AM, Deneer VH. Oxybutynin therapy for generalized hyperhidrosis. Arch Dermatol 2006;142: 1065-6
12. Kowalski JW, Eadie N, Daggett S, lai PY. Validity and reliability of the Hyperhidrosis Disease Severity Scale (HDSS). In: 62nd Annual Meeting of the American Academy of Dermatology. Washington, DC. Poster P198, 6-10 February 2004
13. Stahl SM. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry 2000;48:894-901
14. Mago R, Monti D. Antiadrenergic treatment of antidepressantinduced excessive sweating in 3 patients. J Clin Psychiatry 2007;68:639-40
15. Feder R. Clonidine treatment of excessive sweating. J Clin Psychiatry 1995;56:35
16. Leeman CP. Pathophysiology of tricyclic-induced sweating. J Clin Psychiatry 1990;51:258-9
17. Butt MM. Managing antidepressant-induced sweating. J Clin Psychiatry 1989;50:146-7
18. Salmi P, Ahlenius S. Evidence for functional interactions between 5-HT1A and 5-HT2A receptors in rat thermoregulatory mechanisms. Pharmacol Toxicol 1998;82:122-7
19. Speroff L, Gass M, Constantine G, Olivier S. Effi cacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111:77-87
20. Medgett IC, Fearn HJ, Rand MJ. Serotonin enhances sympathetic vasoconstrictor responses in rat isolated perfused tail artery by activation of postjunctional serotonin-2 receptors. Clin Exp Pharmacol Physiol 1984;11:343-6
21. Ramage AG, Villalon CM. 5-hydroxytryptamine and cardiovascular regulation. Trends Pharmacol Sci 2008;29:472-81
22. Terazosin: Drug information. UpToDate Waltham, MA: UpToDate; 2011.